Investors often rely on the healthcare sector to safeguard their investments. This is because the demand for healthcare services does not vary too much with respect to market conditions, and thus, the sector offers sufficient protection to the capital invested. Many pharmaceutical companies also offer regular dividends. Companies that consistently pay out dividends are financially stable and generate steady cash flows, irrespective of market conditions. Mutual funds are the perfect choice for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight.
Below, we share with you three top-ranked Healthcare mutual funds, namely Fidelity Select Health Care FSPHX, Fidelity Select Biotechnology Portfolio FBIOX and Fidelity Advisor Biotechnology Fund FBTIX. Each has earned a Zacks Mutual Fund Rank #1 (Strong Buy) and is expected to outperform its peers in the future. Investors can click here to see the complete list of funds.
Fidelity Select Health Care focuses on global healthcare stocks, investing in companies providing medical products or services. FSPHX advisors use fundamental analysis to evaluate financial strength, industry position and market conditions, while maintaining a non-diversified portfolio.
Fidelity Select Health Care has three-year annualized returns of 7.9%. As of August 2025, FSPHX held 117 issues, with 7.5% of its assets invested in Boston Scientific.
Fidelity Select Biotechnology Portfolio targets global biotechnology stocks, investing in companies driving scientific and technological advances, and applies fundamental analysis to assess financial health, industry standing and broader market conditions, while maintaining a non-diversified investment approach.
Fidelity Select Biotechnology Portfolio has three-year annualized returns of 16.9%. FBIOX has an expense ratio of 0.63%.
Fidelity Advisor Biotechnology Fund focuses on biotech-related stocks worldwide, targeting firms driving scientific and technological advances, using fundamental analysis to assess financial strength, industry position and broader market conditions, while maintaining a non-diversified portfolio.
Fidelity Advisor Biotechnology Fund has three-year annualized returns of 19.7%. Eirene Kontopoulos has been the fund manager of FBTIX since July 2018.
To view the Zacks Rank and the past performance of all Healthcare mutual funds, investors can click here to see the complete list of healthcare mutual funds.
Want key mutual fund info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >>
Zacks Naming Top 10 Stocks for 2026
Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.
From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5.
Be First to New Top 10 Stocks >>
View All Zacks #1 Ranked Mutual Funds
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Get Your Free (FSPHX): Fund Analysis Report
Get Your Free (FBIOX): Fund Analysis Report
Get Your Free (FBTIX): Fund Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
www.nasdaq.com